| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Mirum Pharmaceuticals (NASDAQ:MIRM) has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 4 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 3 | 2 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $84.25, with a high estimate of $95.00 and a low estimate of $77.00. This current average has increased by 16.48% from the previous average price target of $72.33.
A clear picture of Mirum Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Michael Ulz | Morgan Stanley | Raises | Overweight | $81.00 | $75.00 |
| Joseph Thome | TD Cowen | Announces | Buy | $95.00 | - |
| Jessica Fye | JP Morgan | Raises | Overweight | $77.00 | $53.00 |
| Dae Gon Ha | Stifel | Announces | Buy | $89.00 | - |
| Gavin Clark-Gartner | Evercore ISI Group | Raises | Outperform | $89.00 | $77.00 |
| Jonathan Wolleben | JMP Securities | Raises | Market Outperform | $81.00 | $79.00 |
| Steven Seedhouse | Raymond James | Raises | Strong Buy | $82.00 | $77.00 |
| Swayampakula Ramakanth | HC Wainwright & Co. | Raises | Buy | $80.00 | $73.00 |
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Mirum Pharmaceuticals's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Mirum Pharmaceuticals analyst ratings.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Mirum Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 64.09% as of 30 June, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Mirum Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -4.59%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -2.4%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Mirum Pharmaceuticals's ROA excels beyond industry benchmarks, reaching -0.83%. This signifies efficient management of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.25, caution is advised due to increased financial risk.
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: MIRM
